Prospective Grant of Exclusive License: Hydroxylamine Compositions for the Prevention or Retardation of Cataracts

This notice, in accordance with 35 U.S.C. 209(c))1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, in contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Number 6,001,853 issued December 14, 1999 entitled, "Hydroxylamine Compositions for the Prevention or Retardation of Cataracts", to SL Pharmaceuticals, having a place of business in Kennett Square, PA 19348. The contemplated exclusive license may be limited to use for human therapeutics and diagnostics. The United States of America is the assignee of the patent rights in this invention.